EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

NYVAC-C (vP2010), a recombinant vector expressing HIV subtype C gag, pol, env and nef antigens, was tested in a phase I study in healthy, HIV negative volunteers in London and Lausanne. Twenty-four participants were randomised to receive NYVAC-C (20) or matching placebo (4) at weeks 0 and 4, and ass...

Full description

Bibliographic Details
Main Authors:	Bart, P, Goodall, R, Barber, T, Harari, A, Guimaraes-Walker, A, Khonkarly, M, Sheppard, N, Bangala, Y, Frachette, M, Wagner, R, Liljeström, P, Kraehenbuhl, J, Girard, M, Goudsmit, J, Esteban, M, Heeney, J, Sattentau, Q, McCormack, S, Babiker, A, Pantaleo, G, Weber, J
Format:	Journal article
Language:	English
Published:	2008

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

Similar Items